State Street Corp Decreases Stock Holdings in Natera, Inc. (NASDAQ:NTRA)

State Street Corp lowered its position in shares of Natera, Inc. (NASDAQ:NTRA - Free Report) by 2.2% during the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 3,494,340 shares of the medical research company's stock after selling 78,456 shares during the quarter. State Street Corp owned 2.65% of Natera worth $443,606,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors have also recently modified their holdings of NTRA. Itau Unibanco Holding S.A. purchased a new stake in Natera in the 2nd quarter worth about $28,000. Quarry LP grew its position in Natera by 148.4% during the second quarter. Quarry LP now owns 318 shares of the medical research company's stock worth $34,000 after buying an additional 190 shares in the last quarter. GAMMA Investing LLC raised its stake in Natera by 50.0% in the second quarter. GAMMA Investing LLC now owns 324 shares of the medical research company's stock valued at $35,000 after purchasing an additional 108 shares in the last quarter. Covestor Ltd raised its position in shares of Natera by 34.3% during the 3rd quarter. Covestor Ltd now owns 372 shares of the medical research company's stock valued at $47,000 after buying an additional 95 shares in the last quarter. Finally, True Wealth Design LLC purchased a new position in shares of Natera in the 3rd quarter worth about $57,000. Hedge funds and other institutional investors own 99.90% of the company's stock.

Insider Activity at Natera

In related news, insider Solomon Moshkevich sold 256 shares of the company's stock in a transaction that occurred on Tuesday, October 22nd. The stock was sold at an average price of $120.07, for a total value of $30,737.92. Following the transaction, the insider now directly owns 111,891 shares of the company's stock, valued at approximately $13,434,752.37. This represents a 0.23 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, insider Jonathan Sheena sold 2,700 shares of the business's stock in a transaction on Wednesday, September 18th. The stock was sold at an average price of $127.57, for a total value of $344,439.00. Following the completion of the transaction, the insider now owns 284,741 shares of the company's stock, valued at $36,324,409.37. This represents a 0.94 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 133,976 shares of company stock valued at $21,119,238 in the last 90 days. Corporate insiders own 7.60% of the company's stock.

Analyst Ratings Changes

Several research firms have commented on NTRA. Craig Hallum lifted their price target on shares of Natera from $121.00 to $157.00 and gave the stock a "buy" rating in a research note on Wednesday, November 13th. StockNews.com lowered shares of Natera from a "hold" rating to a "sell" rating in a research report on Thursday, November 14th. Sanford C. Bernstein boosted their target price on Natera from $125.00 to $135.00 and gave the company an "outperform" rating in a research note on Wednesday, October 30th. Robert W. Baird lifted their price target on Natera from $120.00 to $160.00 and gave the stock an "outperform" rating in a research note on Wednesday, November 13th. Finally, JPMorgan Chase & Co. raised their target price on shares of Natera from $135.00 to $160.00 and gave the stock an "overweight" rating in a report on Wednesday, November 13th. One equities research analyst has rated the stock with a sell rating and seventeen have assigned a buy rating to the company's stock. According to MarketBeat.com, Natera has a consensus rating of "Moderate Buy" and a consensus price target of $140.59.

Natera Stock Down 0.8 %

Natera stock traded down $1.35 on Tuesday, hitting $166.45. 1,075,947 shares of the stock traded hands, compared to its average volume of 1,334,799. The business's fifty day simple moving average is $140.97 and its 200 day simple moving average is $123.06. The firm has a market cap of $21.97 billion, a P/E ratio of -95.34 and a beta of 1.63. The company has a current ratio of 4.39, a quick ratio of 4.23 and a debt-to-equity ratio of 0.33. Natera, Inc. has a 1 year low of $55.56 and a 1 year high of $175.63.

Natera (NASDAQ:NTRA - Get Free Report) last posted its quarterly earnings data on Tuesday, November 12th. The medical research company reported ($0.26) EPS for the quarter, topping the consensus estimate of ($0.57) by $0.31. Natera had a negative net margin of 14.01% and a negative return on equity of 26.23%. The business had revenue of $439.80 million for the quarter, compared to analyst estimates of $361.43 million. During the same quarter in the previous year, the firm posted ($0.95) earnings per share. Natera's quarterly revenue was up 63.9% on a year-over-year basis. As a group, sell-side analysts forecast that Natera, Inc. will post -1.61 earnings per share for the current year.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.